mRNA Vaccine for Respiratory Syncytial Virus
Trial Summary
What is the purpose of this trial?
The purpose of this study is to evaluate the safety and immunogenicity an investigational messenger ribonucleic acid (mRN)A vaccine for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) and/or human metapneumovirus (hMPV) in older adults. A single intramuscular (IM) injection of 3 to 4 different doses of the RSV/hMPV mRNA vaccine candidate formulated with 2 different lipid nanoparticles (LNP) will be administered to healthy participants aged 18 to 49 years and 60 years and older.Treatment:* RSV/hMPV mRNA / LNP 1 at 3-4 different doses or,* RSV/hMPV mRNA / LNP 2 at 3-4 difference doses or,* RSV mRNA / LNP 1 at 1 dose or,* hMPV mRNA / LNP 1 at 1 dose
Eligibility Criteria
This trial is for healthy adults aged 18-49 and those 60 or older. Participants must have signed a consent form. They can't join if they have any health issues that might affect the study's results, as judged by the study leader.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single intramuscular injection of the RSV/hMPV mRNA vaccine candidate at various doses
Follow-up
Participants are monitored for safety and immunogenicity, including serum neutralizing antibody titers and adverse events
Treatment Details
Interventions
- hMPV mRNA LNP 1
- RSV/hMPV mRNA LNP 1
- RSV/hMPV mRNA LNP 2
- RSV mRNA LNP 1
Find a Clinic Near You
Who Is Running the Clinical Trial?
Sanofi Pasteur, a Sanofi Company
Lead Sponsor
Paul Hudson
Sanofi Pasteur, a Sanofi Company
Chief Executive Officer since 2019
Degree in Economics from Manchester Metropolitan University
Dr. Thomas Triomphe
Sanofi Pasteur, a Sanofi Company
Chief Medical Officer since 2020
MD from Tehran University of Medical Sciences